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Background:  Cardiac  resynchronization  therapy  (CRT)  is  an  established  treatment  modality  for  advanced
heart  failure  (HF)  but 20–30%  of  patients  treated  with  CRT  do  not  experience  clinical  improvement.  Hence,
in this  study  we  aimed  to investigate  whether  baseline  cardiopulmonary  exercise  testing  (CPX)  can  help
improve  the  prediction  of  a positive  functional  CRT response.
Methods:  This  prospective  observational  study  included  76  HF  patients  undergoing  elective  CRT implan-
tation  and  clinical  CPX  and  echocardiographic  assessment  were  performed  at  baseline,  6, and  12 months.
Results:  Peak  VO2 increased  from  11.0  ± 2.5  ml/min/kg  to 12.0  ±  4.1 ml/min/kg  and 12.2 ±  3.5  ml/min/kg
at  6 and  12  months  after  CRT,  respectively.  The  number  of patients  classiﬁed  as  “CRT-responders” ( peak
VO2 ≥1  ml/kg/min)  was  33  (46%)  and  36  (52%)  at 6 and  12 months  after  CRT,  respectively.  Patients  with
baseline  peak  VO2 <40%  of  predicted  (lowest  tertile)  demonstrated  a 68%  and  69%  response  rate  at 6  and
12  months,  respectively,  as  compared  to a 35%  and  42%  response  rate among  patients  with  baseline  peak
VO2 ≥40%  of  predicted  (p =  0.01  and  p =  0.02,  respectively).  In  multivariate  analysis  patients  with  baseline
peak  VO2 <40%  of  predicted  had  an  adjusted  odds  ratio  of  4.4  (95%  CI 1.6–12.5;  p  < 0.01)  and  3.1  (95% CI
1.1–8.8;  p  =  0.03)  for  positive  CRT  response  at 6  and  12  months,  respectively.
Conclusions:  Treatment  with  CRT improves  exercise  capacity  but this  increase  is  most  substantial  among
patients  with  a lower  baseline  peak  VO2 (% of  predicted).  Baseline  CPX  can,  therefore,  be  utilized  to
identify  patients  more  likely  to  exhibit  a functional  improvement  after  CRT.
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Cardiac resynchronization therapy (CRT) is a relatively recent
dvancement in heart failure (HF) management that aims to
ncrease cardiac output by synchronized pacing of the left and right
yocardial ventricle [1,2]. It has been demonstrated that CRT can
mprove survival, quality of life, HF symptoms, New York Heart
ssociation (NYHA) functional class, endothelial function as well
s exercise capacity in patients with moderate to severe HF dis-
laying evidence of ventricular dyssynchrony [3–6]. According to
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established guidelines, CRT should be considered in patients with
electrocardiographic (ECG) evidence of dyssynchrony (QRS width
≥120 ms)  with left ventricular ejection fraction (LVEF) less than
35%, in NYHA functional class III/IV and receiving optimal medi-
cal treatment regimen for HF [7].  However, despite application of
these selection criteria, 20–30% of HF patients treated with CRT
do not experience clinical improvement [8].  This high frequency
of “non-responders” has important cost-effectiveness implications
and indicates the need for more appropriate patient selection by
correctly identifying patient characteristics that determine positive
response to CRT therapy.
Recently, the multicenter Predictors of Response to CRT
(PROSPECT) study tested the performance of the most commonly
used echocardiographic parameters and found that no single
echocardiographic measure could improve patient selection for
CRT beyond current guidelines [9].  Cardiopulmonary exercise test-
ing (CPX) is regarded as a functional assessment providing an
vier Ltd. All rights reserved.
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ntegrated measure of both central and peripheral abnormalities,
nd has been shown to accurately predict hospitalization and
ortality in HF patients [10–13].  Although CPX can improve sig-
iﬁcantly following CRT [2,14,15], there has been limited focus on
he utility of such functional assessment for CRT patient selection.
PX is particularly useful for determining the optimal timing for
eart transplantation (HTx) [16], but it is unclear whether CRT can
ufﬁciently improve exercise capacity and, hence, allow patients
cheduled for HTx to be delisted. In this prospective study we
ought to (i) explore the effect of CRT on exercise capacity and
n ventilatory expired gas analysis and (ii) to examine if base-
ine CPX could improve the prediction of a positive functional CRT
esponse. To better understand the interaction between exercise
apacity and myocardial remodeling we also evaluated the cor-
elation between improved CPX parameters following CRT and
he parallel change in traditional remodeling indices measured by
chocardiography.
ethods
atient selection
This prospective observational study included 76 consecutive
table HF patients undergoing elective CRT implantation at our
ertiary center. Indications for CRT implantation were in accor-
ance with current guidelines: (i) NYHA functional class III/IV
ith HF secondary to coronary artery disease (CAD) or dilated
ardiomyopathy (DCM); (ii) LVEF ≤35% by any imaging method;
iii) surface ECG QRS width ≥120 ms;  and (iv) optimal HF med-
cal treatment regimen for ≥3 months [17]. Exclusion criteria
ere recent myocardial infarction (MI) or percutanous coro-
ary intervention (PCI) less than 3 months before evaluation,
lanned revascularization, unstable and decompensated HF, severe
alvular pathology other than mitral regurgitation, and previ-
usly implanted pacemakers. The study protocol was  approved
y the Regional Ethics Committee, complies with the Declaration
f Helsinki, and written informed consent was  obtained for all
atients.
All patients in the current study were provided identical HF
anagement following CRT implantation. In particular, patient
edication was carefully monitored according to guidelines and
ide effects, and advice regarding ﬂuid and diet intake was identi-
al for all patients. All patients were encouraged to exercise prior to
RT implantation and no patients participated in additional reha-
ilitation programs.
atient assessment and cardiopulmonary exercise testing
All patients underwent clinical assessment and blood sampling
or N-terminal pro-brain natriuretic peptide (NT-proBNP) mea-
urement at baseline, and at 6 and 12 months following CRT
mplantation. Quality of life was assessed using the short form (SF)-
6 questionnaire [18] and 6-min hall-walk test was performed in
ccordance with standard protocol [19]. Symptom limited CPX was
erformed using a cycle ergometer (Jaeger ER900, VIASYS Health-
are GmbH, Hochberg, Germany) and a stepwise protocol starting
t 25 W with increments of 5 W per minute. Pedal speed was main-
ained at approximately 60 rotations per min. Before each test
he equipment was calibrated using reference gases and oxygen
ptake (VO2), carbon dioxide output (VCO2), and minute venti-
ation were measured on a breath-to-breath basis (MVmax 229,
IASYS Healthcare GmbH). Peak VO2 was deﬁned as the highest
xygen uptake recorded during the last 30 s of exercise. VE/VCO2
lope was calculated by least square linear regression using values
btained throughout the whole exercise. Ventilatory threshold waslogy 60 (2012) 228–235 229
determined using standard graphical methods. Heart rate and
rhythm were continuously recorded, and brachial arterial blood
pressure was  measured every 2 min.
Echocardiography
Resting cardiac echocardiograms were recorded in the left
lateral decubitant position using a commercially available digi-
tal ultrasound scanner (Vivid 7, GE Vingmed Ultrasound, Horten,
Norway). Images were obtained using a 2.5–3.5 MHz  broadband
transducer in two  parasternal and three standard apical views and
2D-gray scale, color Doppler, and tissue Doppler imaging (TDI) data
were obtained. Images were analyzed off-line (EchoPAC 7.0.0, GE
Vingmed Ultrasound, GE Healthcare, Horten, Norway), by a single
physician blinded to the patients’ clinical and functional assess-
ment data. Measurements of left ventricular (LV) dimensions were
obtained according to consensus guidelines [20]. Doppler ultra-
sound has been shown to be a reliable and reproducible tool for
assessment of interventricular delay/dyssynchrony and this was
measured for all patients in the current study [21].
Quality of life
Patients participating in the study answered the Norwegian ver-
sion 1.2 of the SF-36 questionnaire. Responses were related to the
4 weeks preceding the answering and scores were weighted and
aggregated (into 8 dimensions) to obtain a physical component
summary (PCS) and a mental component summary (MCS) score,
and compared to the Norwegian population norm [18].
Device implantation
A biventricular pacemaker device was implanted using local
anesthesia and with the patient in the supine position. Biventric-
ular devices used were CRTs Contak TR2 (n = 26; Guidant Corp., St.
Paul, MN,  USA), InSync III (n = 35; Medtronic Inc., Minneapolis, MN,
USA), and CRT-Ds (biventricular pacemaker including cardioverter-
deﬁbrillator Contak TR4 (n = 1; Guidant Corp.)), InSync Protect
(n = 13, Medtronic Inc.), and InSync Marquis (n = 1; Medtronic Inc).
No major complications were encountered during or after implan-
tation. The day after implantation, the AV-interval was optimized
for maximal diastolic ﬁlling by Doppler echocardiography using
the iterative method. The interventricular pacing interval between
the LV and right ventricular (RV) lead (VV-interval) was  optimized
using pulsed wave Doppler measurements of aortic outﬂow veloc-
ity time integral at different VV-intervals.
Deﬁnition of response to CRT
Peak VO2 deﬁnes a person’s functional aerobic capacity as it rep-
resents the maximal achievable level of oxygen uptake, transport,
and utilization [10]. In this study  peak VO2 ≥1 ml/kg/min was
considered a positive response to CRT based on previous landmark
trials that have established this cut-off as a functional CRT efﬁcacy
endpoint [2,15].
Transplantation listing criteriaThe primary current CPX criteria for HTx listing at our center
is peak VO2 ≤12.0 ml/kg/min for patients receiving -blockers and
peak VO2 ≤14.0 ml/kg/min for patients not receiving such therapy
[16].
230 S. Arora et al. / Journal of Cardiology 60 (2012) 228–235
Table 1
Patient characteristics at baseline, 6 months, and 12 months after cardiac resynchronization therapy.
Baseline (n = 76) 6 months (n = 71) 12 months (n = 69)
Patient demographics
Patient age (years) 64 ± 1.1 – –
Male gender 64 (84%) – –
Atrial  ﬁbrillation 16 (21%) – –
Etiology for CHF
IHD 38 (50%) – –
Cardiomyopathy 38 (50%) – –
Medical therapy
Statin therapy 42 (55%) – –
Beta  blocker 69 (91%) – –
Diuretics 69 (91%) – –
Spironolactone 43 (57%) – –
NYHA  class
I 0 (0%) 2 (3%) 5 (7%)
II 0  (0%) 46 (67%) 46 (67%)
III 66 (87%) 21 (30%) 16 (23%)
IV  10 (13%) 0 (0%) 2 (3%)
NT-proBNP (pmol/L) 374.0 ± 468.9 234.5 ± 278.2 181.7 ± 212.1
QRS  duration (ms) 174.3 ± 2.4 138.3 ± 2.5 135.9 ± 2.2
Quality  of life
Physical combined score 30.4 ± 8.1 38.0 ± 11.2 37.1 ± 10.5
Mental  combined score 42.3 ± 10.3 47.1 ± 11.0 50.5 ± 12.1
6  min  hall test (meters) 483.3 ± 99.2 – 515.8 ± 93.0
Echocardiography
LVEF  (%) 21.9 ± 7.7 27.2 ± 10.3 29.2 ± 11.3
LVESV  (ml) 211 ± 99 173 ± 113 160 ± 107
LVEDV (ml) 266 ± 112 231 ± 133 212 ± 119
IVMD  (ms) 59.1 ± 27.3 28.9 ± 28.4 28.8 ± 31.2
Cardiopulmonary exercise data
Peak VO2 (ml/kg/min) 11.0 ± 2.5 12.0 ± 4.1 12.2 ± 3.5
Peak  VO2 (l/min) 0.95 ± 0.27 1.0 ± 0.4 1.1 ± 0.4
Peak  VO2 (% of predicted) 44.8 ± 11.3 50.0 ± 16.6 51.8 ± 15.4
Watts  57.3 ± 19.8 65.3 ± 26.4 66.8 ± 27.4
Resting sinus rhythm heart rate (bpm) 70.7 ± 10.5 77.6 ± 16.4 75.0 ± 13.1
Peak  sinus rhythm heart rate (bpm) 116.3 ± 28.2 114.0 ± 25.9 112.5 ± 23.0
Resting  AF heart rate (bpm) 69.4 ± 14.2 81.0 ± 17.2 73.9 ± 5.6
Peak  AF heart rate (bpm) 123.7 ± 30.7 107.2 ± 28.1 104.4 ± 28.4
O2 pulse (% of predicted) 54.0 ± 16.9 61.4 ± 19.3 64.9 ± 19.1
VE  peak (l/min) 49.5 ± 13.9 50.0 ± 13.3 51.5 ± 12.1
VE/VCO2 slope 46.1 ± 8.7 44.8 ± 9.3 44.3 ± 8.3
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(HF, congestive heart failure; IHD, ischemic heart disease; NYHA, New York Heart
jection fraction; LVESV, left ventricular end systolic volume; LVEDV, left ventricul
xygen uptake; VCO2, rate of elimination of carbon dioxide; VE, slope of ventilation
tatistical analysis
Analyses were performed with the SPSS statistical software
SPSS Inc. Chicago, IL, USA; v.16.0). Data are expressed as mean ± SD
nd a two-tailed p-value <0.05 was considered statistically signiﬁ-
ant. Student’s t-test was used for normally distributed continuous
ariables and Mann–Whitney test for other continuous variables.
ategorical variables were compared using the chi-square test. The
ssociation between baseline characteristics and the outcome “CRT
esponder”  was initially evaluated by univariate analysis and signif-
cant predictors (two-tailed p < 0.05) were entered into a forward
tepwise logistic regression analysis (continuous variables cate-
orized according to mean/median as appropriate) with criteria
or entry and exit at p < 0.05 and <0.10, respectively. Model per-
ormance was assessed by the Hosmer–Lemeshow goodness-of-ﬁt
est.
esults
Of the 76 patients included in this study, etiology for HF was
oted to be CAD in 38 (50%) patients and DCM in 38 (50%) patients.
aseline peak VO2 was 11.0 ± 2.5 ml/kg/min, LVEF was 21.9 ± 7.7%,
nd left ventricular end systolic volume (LVESV) was 211 ± 99 ml
Table 1). Of the 76 patients, 69 (91%) underwent CPX at baseline, 6,iation; NT-proBNP, N-terminal probrain natriuretic peptide; LVEF, left ventricular
 diastolic volume; IVMD, interventricular motion delay; AF, atrial ﬁbrillation; VO2,
and 12 months after CRT (2 patients underwent HTx, 1 was  operated
for aortic stenosis, 3 died, and 1 patient was lost to follow-up).
Exercise data following CRT
CRT treatment resulted in several changes in exercise parame-
ters (Table 1). Resting heart rate (HR) decreased signiﬁcantly, but
so did peak HR resulting in unchanged HR reserve. Both peak O2
pulse, an indirect measurement of stroke volume, and peak systolic
BP increased, whereas, ventilatory efﬁciency assessed by VE/VCO2
slope decreased (Table 1). The number of patients classiﬁed as “CRT-
responders” ( peak VO2 ≥1 ml/kg/min) was  33 (46%) and 36 (52%)
at 6 and 12 months after CRT, respectively.
Improvement in exercise capacity among CRT responders and
non-responders
When comparing patients classiﬁed as responders ( peak
VO2 ≥1 ml/kg/min) versus non-responders, a signiﬁcant difference
in  peak VO2 (2.9 ± 3.5 ml/kg/min versus −1.0 ± 2.2 ml/kg/min,
p < 0.01),  peak VO2% of predicted (14 ± 14% versus −4 ± 11%,
p < 0.01),  O2 pulse (2.4 ± 3.1 ml/beat versus 0.2 ± 3.0 ml/beat,
p < 0.01),  peak HR (3 ± 28 bpm versus −15 ± 29 bpm, p < 0.01),
 VE peak (5.6 ± 11.0 versus −5.3 ± 13.0, p < 0.01) and  VE/VCO2
(−4.7 ± 8.9 versus 1.9 ± 7.2, p < 0.01) was observed at 6 months after
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LVESV, or LVEF (Fig. 3).
When evaluating baseline markers of dyssynchrony, we
observed that the mean QRS duration was 175 ± 22 ms.  Dyssyn-
chrony measured by pulsed Doppler parameters showed a meanig. 1. Change in exercise capacity and ventilatory gas parameters among patients
2  months of cardiac resynchronization therapy (CRT) (response =  peak VO2 ≥1 m
he  two  groups.
RT (Fig. 1). The observed difference in these exercise capacity
arameters among responders and non-responders was main-
ained at 12 months after CRT (Fig. 1). Improvement in 6-min hall
alking distance after 12 months of CRT was also signiﬁcantly
reater among patients classiﬁed as CRT responders (49.7 ± 67.6 m
ersus −3.0 ± 93.3 m,  p < 0.01).
eterminants of CRT response ( peak VO2 ≥1 ml/kg/min)
Baseline peak VO2 was signiﬁcantly lower among patients
lassiﬁed as responders as compared to non-responders after 12
onths of CRT (Table 2). No signiﬁcant difference in patient demo-
raphics or concomitant medical therapy for HF was noted when
omparing responders versus non-responders (Table 2). Upon clas-
iﬁcation of patients into quartiles according to baseline peak VO2
 negative linear relationship was observed with the most dramatic
mprovement in ventilatory capacity being evident among patients
ith baseline peak VO2 ≤9.4 ml/kg/min (Fig. 2). Patients with base-
ine peak VO2 <40% of predicted (lowest tertile) demonstrated a 68%
esponse rate at 6 months after CRT initiation as compared to a 35%
esponse rate among their counterparts with baseline peak VO2
40% of predicted (p = 0.01). Similarly, after 12 months of CRT, a
9% and 42% response rate was evident among patients with base-
ine peak VO2 <40% and ≥40% of predicted, respectively (p = 0.02).
verall, during the 12-month study period a signiﬁcant increase
n peak VO2 was observed among patients with baseline peak VO2
40% as compared to ≥40% of predicted ( peak VO2 0.2 ± 0.3 l/min
ersus 0.07 ± 0.2 l/min, p = 0.04) but this did not apply to other CRTiﬁed as responders versus non-responders according to increase in peak VO2 after
min). *Refers to p < 0.05 and annotates a statistically signiﬁcant difference between
responses such as the 6-min walk test, physical combined score,Fig. 2. Percent increase in peak VO2 (ml/kg/min) following 12 months of cardiac
resynchronization therapy (CRT) according to baseline exercise capacity (4 groups
represent quartile values).
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Table 2
Baseline characteristics of patients classiﬁed as responders (VO2 peak ≥1 ml/kg/min) versus non-responders (VO2 peak <1 ml/kg/min) after 12 months of cardiac
resynchronization therapy.
Responders (n = 36) Non-responders (n = 33) p-Value
Patient demographics
Patient age (years) 63.7 ± 10.1 64.3 ± 9.7 0.78
Male  gender 31 (86%) 28 (85%) 0.88
Atrial  ﬁbrillation 8 (22%) 6 (18%) 0.68
Etiology  for CHF
IHD 16 (44%) 18 (55%) 0.40
Cardiomyopathy 20 (56%) 15 (45%) 0.40
Medical  therapy
Statin therapy 17 (47%) 21 (64%) 0.17
Beta  blocker 33 (92%) 29 (88%) 0.60
Diuretics 30 (83%) 32 (97%) 0.06
Spironolactone 17 (47%) 21 (64%) 0.60
NYHA class
III 31 (86%) 30 (91%) 0.53
IV 5  (14%) 3 (9%) 0.53
NT-proBNP (pmol/L) 327 ± 324 423 ± 615 0.29
QRS  duration (ms) 176 ± 20 173 ± 21 0.65
Quality of life
Physical combined score 31.2 ± 9.3 30.7 ± 7.2 0.01
Mental  combined score 43.4 ± 11.1 40.9 ± 9.1 0.32
6-min  hall test (meters) 496 ± 84 483 ± 102 0.55
Echocardiography
LVEF  (%) 21.1 ± 7.8 22.5 ± 7.7 0.40
LVESV  (ml) 211.3 ± 95.1 211.5 ± 106.4 0.99
LVEDV  (ml) 263.6 ± 107.7 266.6 ± 119.5 0.92
IVMD  (ms) 63.9 ± 22.5 53.5 ± 30.9 0.04
Cardiopulmonary exercise data
Peak VO2 (ml/kg/min) 10.6 ± 2.3 11.7 ± 2.4 0.04
Peak  VO2 (l/min) 0.9 ± 0.3 1.0 ± 0.3 0.18
Peak  VO2 (% of predicted) 42 ± 10 49 ± 12 0.02
Watts 56.8 ± 20.8 58.4 ± 19.8 0.67
Peak  heart rate (bpm) 114 ± 29 122 ± 28 0.21
Peak  systolic BP (mm  Hg) 131 ± 21 133 ± 27 0.67
O2 pulse (ml/beat) 8.1 ± 2.8 8.8 ± .3.0 0.32
O2 pulse (% of predicted) 53 ± 17 59 ± 16 0.19
VE  peak (l/min) 45.7 ± 12.1 52.5 ± 15.5 0.10
VE/VCO2 slope 46.4 ± 9.9 45.0 ± 7.4 0.53
CHF, congestive heart failure; IHD, ischemic heart disease; NYHA, New York Heart Assoc
ejection fraction; LVESV, left ventricular end systolic volume; LVEDV, left ventricular en
blood  pressure; VCO2, rate of elimination of carbon dioxide; VE, slope of ventilation.
Bold values represent statistically signiﬁcant values (p < 0.05).
Fig. 3. Change in exercise capacity and alternative cardiac resynchronization ther-
apy  response parameters among patients with baseline peak VO2 above and below
40% of predicted (peak VO2 < 40% represents lowest tertile). *Refers to p < 0.05 and
annotates a statistically signiﬁcant difference between the two  groups as compared
by  ANCOVA analysis. 6MWT,  6-min hall-walk test; EF, ejection fraction; LVESV, left
ventricular end systolic volume.iation; NT-proBNP, N-terminal probrain natriuretic peptide; LVEF, left ventricular
d diastolic volume; IVMD, interventricular motion delay; VO2, oxygen uptake; BP,
left ventricular pre-ejection interval (LPEI) of 182 ± 34 ms  and
a right ventricular pre-ejection interval (RPEI) of 125 ± 26 ms,
which gives an estimated mean interventricular motion delay
(IVMD) of 59 ± 28 ms.  Tissue Doppler evaluation of septal-
to-lateral delay was 10 ms  (interquartile range 0–70). After
CRT for 12 months measures of dyssynchrony in the group
as a whole demonstrated a narrowing of the QRS-width to
140 ± 52 ms, LPEI was changed to 188 ± 40 ms, RPEI was  found
to be 164 ± 34 ms  giving a reduction in IVMD to 29 ± 30 ms.
Baseline mean IVMD value was  noted to be signiﬁcantly greater
among responders than non-responders (63.9 ± 22.5 ms versus
53.5 ± 30.9 ms;  p = 0.04).
In a multivariate analysis including patient age, gender, and
all baseline variables signiﬁcantly (p < 0.05) associated with CRT
response at 6 or 12 months (baseline peak VO2, interventric-
ular motion delay, and physical combined score) patients with
baseline peak VO2 <40% of predicted had an adjusted odds
ratio (OR) of 4.4 (95% CI 1.6–12.5; p < 0.01) and 3.1 (95% CI
1.1–8.8; p = 0.03) for positive CRT response at 6 and 12 months,
respectively (Table 3). The p-values for the Hosmer–Lemeshow
goodness-of-ﬁt were 0.69 and 0.72, respectively, showing good
ﬁt of both models. It should be noted that although uni-
variate analysis indicated that increased baseline IVMD was
associated with positive CRT response, multivariate analysis
revealed that this variable was  only an independent predictor
of positive CRT response at 6 months and not at 12 months
(Table 3).
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Table  3
Multivariate analysis of predictors of cardiac resynchronization therapy response (VO2 peak ≥1 ml/kg/min) at 6 and 12 months after device implantation.
Response at 6 months OR (95% CI) p-Value Response at 12 months (OR 95% CI) p-Value
Age (per incremental year) 1.0 (1.0–1.1) 0.18 1.0 (1.0–1.1) 0.60
Male  gender 0.9 (0.2–4.2) 0.91 1.5 (0.3–6.6) 0.58
IVMD  >59 ms 3.4 (1.1–10.4) 0.03 1.8 (0.7–5.2) 0.25
Peak  VO2 >10.4 ml/kg/min 0.7 (0.2–3.0) 0.67 1.0 (0.3–3.5) 0.96
Peak  VO2 <40% of predicted 4.4 (1.6–12.5) <0.01 3.1 (1.1–8.8) 0.03
Physical combined score >30 points 2.7 (0.8–8.7) 0.10 0.81 (0.3–2.3) 0.69
IVMD, interventricular motion delay; VO2, oxygen uptake.
Bold values represent statistically signiﬁcant values (p < 0.05).
Table 4
Patients eligible for heart transplant delisting after 12 months of cardiac resynchronization therapy categorized according to baseline peak VO2 above and below 40% predicted
(criteria for listing considered as peak VO2 <12 ml/kg/min).
Baseline peak VO2 <12 ml/kg/min 12 month peak VO2 <12 ml/kg/min Eligible for delisting
Peak VO2 <40% of predicted (n = 26) 24 (92%) 14 (54%) 10 (35%)
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O2, oxygen uptake.
xercise capacity improvement after CRT and corresponding
hange in remodeling indices
We  found a modest association between  peak VO2 and 
VESV at 6 months after CRT (r = −0.31, p = 0.01), but this associa-
ion was not evident at 12 months after CRT (r = −0.20, p = 0.10).
o signiﬁcant association was found between  peak VO2 and
LVEF at 6 or 12 months after CRT (r = 0.15 and 0.16, respectively,
 > 0.05).
ligibility for HTx listing/delisting following CRT
Overall, 52 (68%) of the study population was  considered eli-
ible for HTx listing using the established criteria for peak VO2.
n total, 69 patients underwent CPX testing at 12 months after
RT and 35 (51%) patients were still eligible for HTx using this
riterion. We  observed that a larger proportion of patients with
aseline peak VO2 <40% of predicted were eligible for HTx delisting
ollowing CRT as compared to their counterparts with base-
ine peak VO2 ≥40% of predicted (35% versus 16%, respectively)
Table 4).
iscussion
The current study has demonstrated that exercise capacity, par-
icularly peak VO2, improves in patients with moderate to severe
F following CRT. We  have explored the role of baseline CPX in
dentiﬁcation of CRT functional responders and demonstrated that
ower baseline VO2 (% of predicted) is associated with a higher
esponse rate as assessed by exercise capacity measurements.
aseline CPX can, therefore, be utilized to identify patients more
ikely to exhibit a functional improvement after CRT. In contrast,
urrent studies on echocardiographic measurements do not sup-
ort the use of this modality alone to determine the likelihood of
RT responses in exercise capacity, and vice versa, the improve-
ent in exercise capacity after device implantation correlates
oorly with improvements in indices of ventricular remodeling.
Overall, a considerable improvement in exercise capacity was
oted in our study population together with an improvement in
-min walk test, echo parameters (LVEF and LVESV), and quality
f life assessment (combined physical score) and this is consistent
ith previously reported CRT studies [3,22].  Our longitudinal data
emonstrated that CRT is associated with a mean improvement
n VO2, O2 pulse, and VE/VCO2 ratio of 9%, 15%, and 10% respec-
ively. There are only limited studies describing the effect of CRT21 (49%) 7 (16%)
on exercise capacity, and it is noteworthy that our results are con-
sistent with the ﬁndings of the landmark MIRACLE study which
demonstrated a near identical level of improvement in peak VO2
after CRT [2].
The measurement of peak VO2 during CPX is an established risk
stratiﬁcation tool for patients with severe HF. This non-invasive
method for characterizing cardiac reserve and functional status is
also considered a reliable method for evaluating response to HF
therapy. When deﬁning a functional CRT response as  peak VO2
≥1 ml/kg/min [2,15],  we observed a 46% and 52% response rate at
6 and 12 months, respectively. Other studies utilizing alternative
measurements of CRT outcome have also reported response rates
varying from 60 to 90% [23]. However, the current study has con-
ﬁrmed that peak VO2 unfortunately does not increase markedly
among a large proportion of patients selected for CRT, and this high-
lights the need for consideration of alternative patient selection
protocols to help improve the likelihood of a positive CRT outcome.
Indeed, our study found that a lower baseline peak VO2 (% of pre-
dicted) was  associated with a positive response to CRT at both 6
and 12 months. Multivariate analysis concluded that patients with
baseline peak VO2 <40% had a 4-fold and 3-fold higher likelihood
of CRT response at 6 and 12 months, respectively. To the best of
our knowledge this ﬁnding has not been reported previously and
suggests the possibility of more appropriate patient selection for
CRT according to baseline CPX. It should be noted that multivariate
analysis did not ﬁnd baseline peak VO2 (ml/kg/min) to determine
CRT response. Although these results may  be interpreted as appar-
ently contradictory, we  believe it is likely to reﬂect the better risk
stratiﬁcation of peak VO2 (% of predicted) as compared to the abso-
lute value (ml/kg/min) which is known to be affected by a multitude
of factors including age, sex, muscle mass, and conditioning status
[24,25]. We  also found it noteworthy that peak VO2 (% of predicted)
was a better predictor of CRT response than mechanical dyssyn-
chrony which has previously been found to be a major determinant
of clinical outcomes after CRT [26].
CPX testing is routinely performed among patients being eval-
uated for HTx listing and international guidelines have been
published to assist appropriate patient selection based on this
assessment [16]. Two  previous studies have demonstrated that
patients who  increase their peak VO2 on serial exercise tests have
improved survival and may  warrant HTx delisting [27,28].  Fur-
thermore, the importance of HR in determining exercise capacity
in CRT patients has been investigated in a recent study and it
was demonstrated that chronotropic incompetence is an impor-
tant determinant of peak exercise capacity [29]. With reference to
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hese ﬁndings, we noted a surprising decline in peak HR following
RT and this may  reﬂect inadequate device programming. Hence,
e would suggest that routine assessment of exercise capacity
ith particular emphasis on evaluation of HR response should be
ncluded in the management of patients selected for CRT.
Our study demonstrated that exercise capacity improved sub-
tantially with CRT, but this improvement was not correlated with
he improvement in some markers of myocardial remodeling (i.e.
VEF and LVESV). Hence, our current study suggests that the change
n exercise capacity is not necessarily “dependent” on LVEF or
ther markers of myocardial dysfunction. In fact, while myocar-
ial remodeling is essential for the development of severe HF,
everal of the symptoms related to this disorder such as fatigue
nd dyspnea with exercise may  not necessarily merely reﬂect
he degree of myocardial failure. Furthermore, it has been sug-
ested that these symptoms at least in part may  be secondary
o other mechanisms such as endocrine abnormalities, autonomic
erve dysfunction, and systemic and local (i.e. within the muscles)
ow-grade inﬂammation. Although we have no mechanistic data,
ur ﬁndings may  further support that myocardial remodeling and
evelopment of impaired exercise capacity, at least partly, reﬂect
eparate mechanisms in the development of HF and this warrants
urther investigation in future studies.
This study is an observational longitudinal study and the lack of
 randomized design with a control arm requires that our results be
nterpreted carefully. Moreover, this was not a mechanistic study,
nd correlations do not necessarily mean any causal relationship.
evertheless, a relatively large number of patients were studied
nd our novel ﬁndings regarding the role of baseline CPX in pre-
icting CRT response should be viewed as hypothesis-generating
hat require further validation in a prospective, randomized trial. It
hould also be borne in mind that the magnitude of a response to an
ntervention is often greater in patients with a greater impairment
f a measure at baseline (“ceiling effect”) and this could potentially
ave accounted for the current study results. However, it should be
oted that the absolute (and not just the percentage) improvement
n peak VO2 was signiﬁcantly greater among patients with baseline
eak VO2 <40%. Furthermore, a signiﬁcantly larger proportion of
atients with baseline peak VO2 <40% were eligible for HTx delist-
ng (criteria for delisting peak VO2 ≥12 ml/kg/min) conﬁrming that
his baseline parameter is a useful predictor of a functional and
linically relevant response to CRT.
onclusions
Treatment with CRT results in improved exercise capacity but
his increase is most substantial among patients with a lower base-
ine peak VO2 (% of predicted). Baseline CPX can, therefore, be
tilized to identify patients more likely to exhibit a functional
mprovement after CRT.
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